CD4 T-cell responses to combination antiretroviral therapy

Lancet

Volumn 370, Issue 9585, 2007, Pages 366-368

  Maartens, Gary ^a   Boulle, Andrew ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CD4+ T LYMPHOCYTE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; PRIORITY JOURNAL;

EID: 34547446112     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(07)60949-0     Document Type: Note

References (11)

1. Battegay M., Nüesch R., Hirschel B., and Kaufmann G. Immunological recovery and antiretroviral therapy in HIV-1 infection. Lancet Infect Dis 6 (2006) 280-287
2. Kaufmann G., Furrer H., Ledergerber B., et al. Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/μL in HIV type-1 infected individuals receiving potent antiretroviral therapy. Clin Infect Dis 41 (2005) 361-372
3. Moore R., and Keruly J. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression. Clin Infect Dis 44 (2007) 441-446
4. Ledergerber B., Lundgren J., Walker A., et al. Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. Lancet 364 (2004) 51-62
5. Mocroft A., Phillips A., Gatell J., and for the EuroSIDA study group. Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study. Lancet (2007). published online July 19. DOI:10.1016/S0140-6736(07)60948-9
6. Braitstein P., Brinkhof M., Dabis F., et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 367 (2006) 817-824
7. Olsen C., Gatell J., Ledergerber B., et al. Risk of AIDS and death at given HIV-RNA and CD4 cell counts, in relation to specific antiretroviral drugs in the regimen. AIDS 19 (2005) 319-330
8. Lange C., Lederman M., Medvik K., et al. Nadir CD4+ T-cell count and numbers of CD28+ CD4+ T-cells predict functional responses to immunizations in chronic HIV-1 infection. AIDS 17 (2003) 2015-2023
9. Siddique M., Hartman K., Dragileva E., et al. Low CD4+ T cell nadir is an independent predictor of lower HIV-specific immune responses in chronically HIV-1-infected subjects receiving highly active antiretroviral therapy. J Infect Dis 194 (2006) 661-665
10. Egger M., May M., Chêne G., et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 360 (2002) 119-129
11. Hogg R., Yip B., Chan K., et al. Rates of disease progression by baseline CD4 count and viral load after initiating triple-drug therapy. JAMA 286 (2001) 2568-2577